KALA BIO Inc. (KALA)
NASDAQ: KALA
· Real-Time Price · USD
1.41
-0.10 (-6.62%)
At close: Oct 15, 2025, 3:59 PM
1.42
0.71%
After-hours: Oct 15, 2025, 07:19 PM EDT
-6.62% (1D)
| Bid | 1.37 |
| Market Cap | 9.9M |
| Revenue (ttm) | 254K |
| Net Income (ttm) | -37.23M |
| EPS (ttm) | -5.96 |
| PE Ratio (ttm) | -0.24 |
| Forward PE | -0.47 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.49 |
| Volume | 677,293 |
| Avg. Volume (20D) | 1,115,198.3 |
| Open | 1.50 |
| Previous Close | 1.51 |
| Day's Range | 1.35 - 1.51 |
| 52-Week Range | 1.10 - 20.60 |
| Beta | -2.11 |
| Ex-Dividend Date | n/a |
About KALA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol KALA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for KALA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts2 weeks ago
-25.37%
Kala Bio shares are trading lower after its Phase ...
Unlock content with
Pro Subscription
2 weeks ago
-89.24%
Kala Bio shares are trading lower after its Phase 2b clinical trial of KPI-012 for persistent corneal epithelial defect failed to meet the primary endpoint.
